Pentamethylquercetin generates beneficial effects in monosodium glutamate-induced obese mice and C2C12 myotubes by activating AMP-activated protein kinase

Diabetologia

Volumn 55, Issue 6, 2012, Pages 1836-1846

  Shen, J Z ^b   Ma, L N ^b   Han, Y ^a   Liu, J X ^a   Yang, W Q ^a   Chen, L ^a   Liu, Y ^b   Hu, Y ^b,c   Jin, M W ^a,b,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province   (China)

^c Wuhan Institute of Biotechnology   (China)

Author keywords

Monosodium glutamate; Pentamethylquercetin; Syndrome

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANTIOBESITY AGENT; CHOLESTEROL; GLUCOSE; GLUCOSE TRANSPORTER 4; GLUTAMATE SODIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PENTAMETHYLQUERCETIN; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; QUERCETIN; SLC2A4 PROTEIN, MOUSE;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE CONTROL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; METABOLIC DISORDER; MOUSE; MYOTUBE; NONHUMAN; OBESITY; PRIORITY JOURNAL; TISSUE LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ANIMAL; BLOOD; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; WEIGHT GAIN; WESTERN BLOTTING;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CHOLESTEROL; GLUCOSE TRANSPORTER TYPE 4; INSULIN RESISTANCE; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; OBESITY; QUERCETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM GLUTAMATE; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 84865443163     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2519-z     Document Type: Article

References (49)

1. Cornier MA, Dabelea D, Hernandez TL et al (2008) The metabolic syndrome. Endocr Rev 29:777-822
2. Simmons RK, Alberti KG, Gale EA et al (2010) The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53:600-605
3. Leverve XM, Guigas B, Detaille D et al (2003) Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29:6S88-6S94 (Pubitemid 37187095)
4. Meriden T (2004) Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 26:177-190 (Pubitemid 38339010)
5. Fryer LG, Parbu-Patel A, Carling D (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226-25232 (Pubitemid 34951829)
6. Dailey GE III (2004) Improving oral pharmacologic treatment and management of type 2 diabetes. Manag Care 13:41-47
7. Steinberg GR, Kemp BE (2009) AMPK in health and disease. Physiol Rev 89:1025-1078
8. Luo Z, Saha AK, Xiang X, Ruderman NB (2005) AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26:69-76 (Pubitemid 40170168)
9. Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9:407-416
10. Jung M, Park M, Lee HC, Kang YH, Kang ES, Kim SK (2006) Antidiabetic agents from medicinal plants. Curr Med Chem 13:1203-1218
11. Wang HX, Ng TB (1999) Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities. Life Sci 65:2663-2677
12. Crozier A, Del RD, Clifford MN (2010) Bioavailability of dietary flavonoids and phenolic compounds. Mol Aspects Med 31:446-467
13. Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751
14. Ahn J, Lee H, Kim S, Park J, Ha T (2008) The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun 373:545-549
15. Eid HM, Martineau LC, Saleem A et al (2010) Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant Vaccinium vitis-idaea. Mol Nutr Food Res 54:991-1003
16. Walle UK, Walle T (2007) Bioavailable flavonoids: cytochrome P450-mediated metabolism of methoxyflavones. Drug Metab Dispos 35:1985-1989 (Pubitemid 350005205)
17. Li RW, Theriault AG, Au K et al (2006) Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Life Sci 79:365-373 (Pubitemid 44172805)
18. Lee YS, Cha BY, Saito K et al (2010) Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem Pharmacol 79:1674-1683
19. Hibasami H, Mitani A, Katsuzaki H, Imai K, Yoshioka K, Komiya T (2005) Isolation of five types of flavonol from seabuckthorn (Hippophae rhamnoides) and induction of apoptosis by some of the flavonols in human promyelotic leukemia HL-60 cells. Int J Mol Med 15:805-809
20. Patanasethanont D, Nagai J, Yumoto R et al (2007) Effects of Kaempferia parviflora extracts and their flavone constituents on P-glycoprotein function. J Pharm Sci 96:223-233 (Pubitemid 46087352)
21. Chen L, He T, Han Y, Sheng JZ, Jin S, Jin MW (2011) Pentamethylquercetin improves adiponectin expression in differentiated 3T3-L1 cells via a mechanism that implicates PPARgamma together with TNF-alpha and IL-6. Molecules 16:5754-5768
22. Wang Y, Xin X, Jin Z et al (2011) Anti-diabetic effects of pentamethylquercetin in neonatally streptozotocin-induced diabetic rats. Eur J Pharmacol 668:347-353
23. Sasaki Y, Shimada T, Iizuka S et al (2011) Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. Eur J Pharmacol 662:1-8
24. Maletinska L, Toma RS, Pirnik Z et al (2006) Effect of cholecystokinin on feeding is attenuated in monosodium glutamate obese mice. Regul Pept 136:58-63
25. de Pedro N, Martinez-Alvarez R, Delgado MJ (2006) Acute and chronic leptin reduces food intake and body weight in goldfish (Carassius auratus). J Endocrinol 188:513-520
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
27. Canto C, Gerhart-Hines Z, Feige JN et al (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458:1056-1060
28. Yin J, Gao Z, Liu D, Liu Z, Ye J (2008) Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 294:E148-E156
29. Grundy SM (2008) Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28:629-636 (Pubitemid 351651324)
30. Yudkin JS (2007) Insulin resistance and the metabolic syndrome-or the pitfalls of epidemiology. Diabetologia 50:1576-1586 (Pubitemid 47036656)
31. Kassi E, Pervanidou P, Kaltsas G, Chrousos G (2011) Metabolic syndrome: definitions and controversies. BMC Med 9:48
32. He T, Chen L, Chen Y, Han Y, Yang WQ, Jin MW (2011) In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. Cardiovasc Drugs Ther. doi:10.1007/s10557-011-6363-z
33. Ikegawa T, Ohtani H, Koyabu N et al (2002) Inhibition of Pglycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett 177:89-93 (Pubitemid 34102403)
34. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15-25 (Pubitemid 43960587)
35. Huang S, Czech MP (2007) The GLUT4 glucose transporter. Cell Metab 5:237-252 (Pubitemid 46477860)
36. Merrill GF, Kurth EJ, Hardie DG, Winder WW (1997) AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 273:E1107-E1112
37. Zheng D, MacLean PS, Pohnert SC et al (2001) Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 91:1073-1083 (Pubitemid 32803899)
38. Ferre P (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53(Suppl 1):S43-S50 (Pubitemid 38168692)
39. Brandt JM, Djouadi F, Kelly DP (1998) Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 273:23786-23792 (Pubitemid 28435712)
40. Knauf C, Rieusset J, Foretz M et al (2006) Peroxisome proliferatoractivated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: Role in liver and brain. Endocrinology 147:4067-4078 (Pubitemid 44268360)
41. Chen H, Dardik B, Qiu L et al (2010) Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys. Endocrinology 151:3115-3124
42. Soyal S, Krempler F, Oberkofler H, Patsch W (2006) PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia 49:1477-1488 (Pubitemid 43848083)
43. Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10:355-361 (Pubitemid 38508511)
44. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956
45. Lim CT, Kola B, Korbonits M (2010) AMPK as a mediator of hormonal signalling. J Mol Endocrinol 44:87-97
46. Zheng J, Ramirez VD (2000) Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 130:1115-1123 (Pubitemid 30453547)
47. Hawley SA, Ross FA, Chevtzoff C et al (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11:554-565
48. Lee YK, Park SY, Kim YM, Lee WS, Park OJ (2009) AMP kinase/ cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. Exp Mol Med 41:201-207
49. Meares GP, Hughes KJ, Naatz A et al (2011) IRE1-dependent activation of AMPKin response to nitric oxide. Mol Cell Biol 31:4286-4297